2024 CMR Board Exam Review Course
Society for Cardiovascular Magnetic Resonance CMR Board Exam Review Course
Format (Online Live, Online In-Person, Enduring, etc.) Online Virtual Webinar Meeting Dates Live: 20-21 April 2024
Meeting Location: Virtual
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Support
No financial commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit for individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Stated Practice Gap(s)
Knowledge Gap: Practitioners may lack comprehensive knowledge, skills, and abilities in preparing patients for CMR studies, selecting appropriate protocols, conducting CMR studies in various scenarios, post-processing images, and interpreting results for clinical decision-making.
Protocol Selection Gap: Physicians may lack the ability to select and perform appropriate protocols for specific clinical scenarios, including understanding when and how to apply different protocols based on patient characteristics and clinical indications.
Interpretation Gap: Practitioners need further training in interpreting normal and abnormal CMR exams, including anatomy, function, and physiology in order to be able to recognize patterns indicative of ischemic and nonischemic heart disease, as well as interpreting additional CMR exams such as those for cardiac masses, congenital heart disease, and vascular disease.
Post-Processing Gap: There is a lack of essential training in the ability to supervise and/or perform post-processing tasks related to CMR exams, which are critical for generating accurate and clinically relevant results.
Certification Preparation Gap: Practitioners may lack preparation specifically for passing the CBCMR Exam, which requires a deep understanding of the above-mentioned areas.
Learning Needs:
- Comprehensive Knowledge of CMR Studies: Practitioners need training to develop a comprehensive understanding of CMR studies, including the principles of CMR imaging, patient preparation techniques, and the ability to select appropriate protocols for different clinical scenarios.
- Protocol Selection Skills: Physicians require training to enhance their ability to select and perform appropriate protocols for specific clinical scenarios. This includes understanding the criteria for selecting protocols based on patient characteristics and clinical indications.
- Interpretation Skills: Practitioners need further training in interpreting normal and abnormal CMR exams. This includes understanding anatomy, function, and physiology related to CMR, as well as recognizing patterns indicative of various heart diseases and other conditions.
- Post-Processing Skills: There is a need for training in supervising and performing post-processing tasks related to CMR exams. This training is essential for generating accurate and clinically relevant results.
- Certification Preparation: Practitioners require preparation specifically for passing the CBCMR Exam. This preparation should focus on deepening their understanding of CMR imaging principles, protocol selection, image interpretation, and post-processing tasks.
- Clinical Decision-Making Skills: Training should focus on developing skills related to using CMR imaging results for clinical decision-making. This includes understanding how to integrate CMR findings into patient management plans.
- Continuing Education: Practitioners should engage in ongoing education to stay updated with advancements in CMR imaging technology, protocols, and interpretation techniques.
Expected Results Statement:
Upon completion of the training program, practitioners will demonstrate comprehensive knowledge, skills, and abilities in cardiovascular magnetic resonance (CMR) imaging. They will be able to prepare patients effectively for CMR studies, select and perform appropriate protocols for various clinical scenarios, interpret normal and abnormal CMR exams accurately, supervise and perform post-processing tasks related to CMR imaging, and integrate CMR findings into clinical decision-making processes. Additionally, practitioners will be prepared to pass the CBCMR Exam, showcasing their deep understanding of CMR principles and practices. Overall, practitioners will be equipped to provide high-quality CMR imaging services, leading to improved patient care and outcomes.
Learning Objectives:
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:
- Select and perform appropriate protocols for specific clinical scenarios.
- Perform CMR exams.
- Interpret normal and abnormal CMR exams: anatomy, function, and physiology.
- Interpret ischemic and nonischemic heart disease CMR Exams
- Interpret additional CMR exams including cardiac masses, congenital heart disease, and vascular disease.
- Supervise and/or perform post processing tasks.
Accreditation Statement
Society for Cardiovascular Magnetic Resonance (SCMR) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
SCMR designates this live/virtual activity for a maximum of 17.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
The following planners/reviewers who were in a position to control the content of this CME activity have disclosed the following financial relationships with ACCME defined ineligible companies. Planners/reviewers not listed below did not have any financial relationships to disclose.
|
First Name
|
Last Name
|
Individual's Role(s) in Activity
|
Name(s) of Ineligible Companies
|
Nature of Relevant Financial Relationship(s)
|
Method of Mitigation
|
|
Vanessa
|
Ferreira
|
Speaker, Chair, Planning Committee
|
General Electric Healthcare
|
Research Grant Site Principal Investigator
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine that no conflict is present
|
|
Kate
|
Hanneman
|
Speaker, Planning Committee
|
Sanofi Genzyme
|
Speakers Bureau
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Kanae
|
Mukai
|
Speaker, Planning Committee
|
Canon Medical Systems
|
Speakers Bureau
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Ming Yen
|
Ng
|
Speaker, Planning Committee, Chair
|
GE, BAYER
|
Other,Other
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Prabhakar
|
Rajiah
|
Speaker, Moderator, Planning Committee
|
Elsevier
|
Other
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Kevin
|
Steel
|
Speaker, Planning Committee
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Katie
|
Thomas
|
Speaker, Planning Committee
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Rachel
|
Wald
|
Speaker, Planning Committee
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
The following faculty (presenters, moderators, chairs, etc.) who were in a position to control the content of this CME activity have disclosed the following financial relationships with ACCME defined ineligible companies. Faculty not listed below did not have any financial relationships to disclose.
|
First Name
|
Last Name
|
Individual's Role(s) in Activity
|
Name(s) of Ineligible
Companies
|
Nature of Relevant Financial
Relationship(s)
|
Method of Mitigation
|
|
Nay
|
Aung
|
Moderator/Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Sonya
|
Babu- Narayan
|
Moderator/Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
James
|
Carr
|
Speaker
|
Siemens,RoClub,GE,Bay er,Guerbet
|
Research Grant Site Principal Investigator,Scientific/Me dical Advisory Board Member,Scientific/Medic al Advisory Board Member,Scientific/Medic al Advisory Board Member,Research Grant
Site Principal Investigator
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine that no conflict is present
|
|
Erica
|
Dall'Armellin a
|
Moderator
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Alison
|
Fletcher
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Marianna
|
Fontana
|
Speaker
|
Consultancy/advisoy boards for Alnylam, Alexion, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia, Ionis, Cardior, Lexeo, Pfizer. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfize,Shares: Lexeo,
Mycardium-AI
|
Consultant,Private Stock Shareholder
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine that no conflict is present
|
|
Marco
|
Francone
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Matthias
|
Friedrich
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Edward
|
Hulten
|
Moderator
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Ron
|
Jacob
|
Moderator
|
Circle CV1
|
Other
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Dinesh
|
Kalra
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Peter
|
Kellman
|
Moderator/Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Christopher
|
Kramer
|
Speaker
|
BMS,Cytokinetics,Biom arin
|
Research Grant Site Principal Investigator,Research
|
The COI subcommittee has reviewed all financial disclosures and the content of
|
|
|
|
|
|
Grant Site Principal Investigator,Scientific/Me dical Advisory Board
Member,Consultant
|
this activity and determine that no conflict is present
|
|
Steve
|
Leung
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Chris
|
Macgowan
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Viviana
|
Maestrini
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Charlotte
|
Manisty
|
Speaker
|
MycardiumAI,Pfizer,Ab bott St Jude Medical
|
Corporate Board Member,Speakers Bureau,Speakers Bureau
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Pier Giorgio
|
Masci
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Rebecca
|
Mills
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Michael
|
Morris
|
Moderator
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Kristian
|
Mortensen
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Saul
|
Myerson
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Faisal
|
Nabi
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Ntobeko
|
Ntusi
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Karen
|
Ordovas
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Alessia
|
Pepe
|
Speaker
|
Circle Cardiovascular Imaging B.V.
|
Speakers Bureau
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Steffen
|
Petersen
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Stefan
|
Piechnik
|
Moderator
|
General Electric
|
Research Grant Overall Principal Investigator
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Vikas
|
Rathi
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
Damian
|
Tyler
|
Speaker
|
NA
|
NA
|
The COI subcommittee has reviewed all financial disclosures and the content of this activity and determine
that no conflict is present
|
|
